Metformin for the treatment of polycystic ovary syndrome (PCOS)

Satin S. Patel, Victor E. Beshay, Bruce R. Carr

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Because of the high prevalence of insulin resistance, there is a growing interest in the application of insulin sensitizing agents in patients with polycystic ovary syndrome (PCOS). Metformin is the most widely prescribed insulin sensitizing agent in patients with PCOS. In this chapter, we address the importance of lifestyle modification as the initial intervention in patients with PCOS. Furthermore, we discuss the efficacy of metformin compared to low-dose estrogen/progestin oral contraceptives in restoring menstrual cyclicity, reducing androgen excess, and protecting against uterine malignancies. Additionally, the role of metformin in PCOS patients with infertility is addressed.

Original languageEnglish (US)
Title of host publicationBiennial Review of Infertility
Subtitle of host publicationVolume 1
PublisherHumana Press
Pages21-28
Number of pages8
ISBN (Print)9781603273916
DOIs
StatePublished - Dec 1 2009

    Fingerprint

Keywords

  • Androgen
  • Anovulation
  • Hyperinsulinemia
  • Metformin
  • PCOS
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Patel, S. S., Beshay, V. E., & Carr, B. R. (2009). Metformin for the treatment of polycystic ovary syndrome (PCOS). In Biennial Review of Infertility: Volume 1 (pp. 21-28). Humana Press. https://doi.org/10.1007/978-1-60327-392-3_2